Trial Profile
An Active-treatment Study of the Efficacy of Ziv-aflibercept in Patients With Neovascular Age-Related Macular Degeneration
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 07 Oct 2020
Price :
$35
*
At a glance
- Drugs Aflibercept (Primary) ; Bevacizumab; Ranibizumab
- Indications Wet age-related macular degeneration
- Focus Therapeutic Use
- Acronyms ZEBRA
- 05 Oct 2020 Status changed from active, no longer recruiting to completed.
- 02 Oct 2019 Planned End Date changed from 7 Jul 2020 to 7 Dec 2020.
- 02 Oct 2019 Planned primary completion date changed from 7 Dec 2018 to 7 Jul 2020.